We continue analysis of the phenotype of human melanoma cell Mel Ibr subclone obtained previously by treatment of the parental cell line by chicken embryo extract. The present study is focused on detection of markers of epithelial-mesenchymal transition that determine enhanced metastatic and invasive potential of malignant tumors of various locations. Analysis of the expression of E-cadherin and vimentin genes in the subclone and parental cells detected activation of epithelial-mesenchymal transition in the subclone. Immunological markers CD90, CD271, and CD95 were present in the parental population, but were not detected on the subclone cells. In contrast to the parental line, cells of the analyzed subclone retain viability in serum-free medium and formed vessel-like structures characteristic of vasculogenic mimicry.

In this review we discuss some biological activities of quinazolinon derivatives. The derivatives of quinazolinon possess their activity by binding to some proteins important for the survival, proliferation and metastasis of tumor cells. There are grounds to initiate clinical trials of these substances to create new treatment protocols for a wide range of cancer diseases, several parasitic diseases, and certain neurodegenerative diseases.

MAb against the antigen CD117 - stem marker of human tumor cells. Strain 406 PPI prepared by cell fusion of mouse myeloma NS-1 cells with spleen mice BALB/ C, pre-immunized three times at an interval of two weeks, the cells of the cell line of human melanoma melKor. Merging conducted using a solution of PEG/DMSO. For screening received mAb 406 used human melanoma cell lines which differed in the expression of CD117 antigen FSBSI "N.N. Blokhin RCRC" collection. N.N Blokhin. Antigen expression was studied in immunofluorescence and evaluated on a flow cytometer BD FACS CantoTMII. ICA IC0-406 was compared with commercial ICA against antigen CD 117 (Germany). The results indicated the identity of the frequency of antigen-positive cases and the percentage of antigen cells. ICA IC0-406 block binding to cells melKor ICA anti-CD117. Linking ICA IC0-406 antigen-positive cells causes modulation of antigen CD 117.

Background. The effectiveness of cancer neoantigen peptide vaccines depends on the presence of an adjuvant in their composition. Poly(I:C), a TRL-3 agonist, is used as an adjuvant in mouse models of cancer vaccines, but has limitations for use in humans. Therefore, the search for new effective adjuvants for inclusion in the composition of cancer neoantigen peptide vaccine is relevant. Ridostin Pro is a domestic drug that contains a natural complex of sodium salts of double-chiral and single-chiral ribonucleic acids, is an agonist of TLR-3, an inducer of interferon, its antiviral activity is shown. In this regard, the study of Ridostin Pro as an adjuvant in the composition of neoantigen peptide vaccines is of interest.Aim. To evaluate the ability of Ridostin Pro and Poly(I:C) adjuvants enhance the specific T-cell response to neoantigen synthetic peptides; to study the antitumor efficacy of a neoantigen peptide vaccine with Ridostin Pro or Poly(I:C) adjuvants.Materials and methods. Immunogenicity of peptides after vaccination with Ridostin Pro or Poly(I:C) adjuvants evaluated with ELISpot. Antitumor effect of Ridostin Pro or Poly(I:C) adjuvants were evaluated on a mouse model of the B16-F10 tumor by the effect on the tumor growth rate and survival of mice.Results. Vaccination of mice with Ridostin Pro or Poly(I:C) with neoantigen peptides contributed to the appearance of a specific immune response to peptides that were part of the vaccine. Ridostin Pro, both as part of a vaccine model and when administered without a peptide, inhibits tumor growth and increases the life expectancy of mice with melanoma B16-F10.Conclusion. Ridostin Pro promotes the formation of a specific immune response to the peptide vaccine, enhances the antitumor effect of the vaccine. These results confirm that Ridostin Pro may prove to be an effective adjuvant for personalized neoantigen peptide vaccines.